Eimer says, is that this is a preventable problem when its on a clinicians radar
nejm.org/doi/full/10.10 A Pill for Obesity
Compounded oral GLP-1 receptor agonist, 3mg to 24mg daily across six dose levels
atide etc.), By Duration (Long-acting GLP-1 Receptor Agonists, Short-acting GLP-1 Receptor Agonists), By Application (Type-2 Diabetes Mellitus, Obesity & Weight Management, Cardiovascular, Others), By Route of Administration (Oral, Injectable, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and others Read more Healthcare Mar 2026 Pages 450 Report Format: PDF, Excel, PPT Global GLP-1 Receptor Agonist Market Projected 3.66% CAGR from 2026 to 2032 Study Period 2026-2032 Market Size (2026) USD 63.2 Billion Market Size (2032) USD 78.4 Billion Largest Region North America Projected CAGR 3.66% Leading Segments By Product Type: Semaglutide Global GLP-1 Receptor Agonist Market Report Key Takeaways: Market size was valued at around USD 52.39 billion in 2025 and is projected to grow from USD 63.2 billion in 2026 to USD 78.4 billion by 2032
For example, gastro-oesophageal reflux disease (GORD) is listed as a common side effect (affecting up to 1 in 10 people) with semaglutide (Wegovy), while dyspepsia (indigestion) is common with several agents in this class
It allows researchers to measure microglial activation and drug effects in a human brain-like tissue construct without requiring access to actual patient brain tissue
